Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-24
2009-11-17
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S277000, C514S646000, C514S734000, C514S741000, C546S192000, C564S305000, C568S743000, C568S811000, C568S828000
Reexamination Certificate
active
07618966
ABSTRACT:
The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula Iwherein Y, Q, Z, R, R1and R2are as defined in the specification.The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.
REFERENCES:
patent: 2002/0137961 (2002-09-01), Bradley et al.
patent: 2002/0161041 (2002-10-01), Browning et al.
patent: 2003/0180234 (2003-09-01), Love et al.
patent: 2005/0282902 (2005-12-01), Chen et al.
patent: 2005/0282912 (2005-12-01), Chen et al.
patent: 2005/0282913 (2005-12-01), Chen et al.
patent: 2006/0247321 (2006-11-01), Chen
patent: 2007/0249581 (2007-10-01), Chen et al.
patent: 2007/0249596 (2007-10-01), Chen et al.
patent: 2007/0249731 (2007-10-01), Chen et al.
patent: 2839836 (1979-03-01), None
patent: 0119087 (1984-09-01), None
patent: 0492904 (1992-07-01), None
patent: WO 03/091189 (2003-11-01), None
patent: WO 2006/001982 (2006-01-01), None
patent: WO 2006/007227 (2006-01-01), None
patent: WO 2007/008548 (2007-01-01), None
Peter C. Astles, et al, Selective Endothelin A Receptor Antagonists, 41 J. Med. Chem. 2732, 2734 (1998).
Howlett et al, “International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors”, Pharmacological Reviews, 54: 2002, pp. 161-202.
Cieplak et al, “Reversal of π-Facial Diastereoselection upon Electronegative Substitution of the Substrate and the Reagent”, J. Am. Chem. Society, 1989, 111, pp. 8447-8462.
Micovic et al, “The synthesis of lactam analogues of fentanyl”, J. Chem. Soc., Perkin Trans 1, 1996, pp. 2041-2050.
Wagner et al, “Mesenteric Vasodilation Mediated by Endothelial Anandamide Receptors”, Hypertension. 33 [part II], 1999, pp. 429-434.
Jarai et al, Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors, PNAS, vol. 96, No. 24, 1999, pp. 14136-14141.
Pisanenko et al, “Anti Microbial Activity of Cyclo Alkenyl Phenos and 4-Alpha Arylcyclopentyl Phenols”, Pharmaceutical Chemistry Journal, vol. 10, No. 10, 1997.
Adams et al, “Structure of Cannabidiol. IV. The position of the linkage between the two rings”, J. Am. Chem. Soc., vol. 62, pp. 1774-1775, 1940.
Fujikawa et al, Antiseptics for foods. LXXIII. 3-Halo-4-hydroxy benzoic acid esters, 4-alkylresorcinol, 4-arylresorcinol, . . . , Chemical Abstracts Database, XP00244503, 1972.
Arnoldi et al, “Analogues of Cannabinoids, Synthesis of N-Heterocyclic Derivatives of Olivetol”, J. Chem., XP009087450, 1983.
Yorio et al, “New therapies for glaucoma: Are they all up to the task?”, Expert Opinion on Therapeutic Patents 2004, vol. 14, No. 12, pp. 1743-1762, 2004.
Chen June
Fliri Hans
Pettit Simon
Allergan Inc.
Basquill Sean
Condino Debra D.
German Joel B.
Krass Frederick
LandOfFree
Abnormal Cannabidiols as agents for lowering intraocular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Abnormal Cannabidiols as agents for lowering intraocular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Abnormal Cannabidiols as agents for lowering intraocular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4069009